Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Bright-light therapy may reduce attention lapses during night work

11

Aug 2026

Bright-light therapy may reduce attention lapses during night work

Light therapy may improve alertness and attention/reaction time during simulated night shifts, with the strongest benefits appearing after light exposure. Effects on executive function were smaller and largely limited to treatment, while substantial study heterogeneity and limited real-world evidence warrant caution.

One cognitive ability stood out in a study of Western diets and Alzheimer’s risk genes

11

Aug 2026

One cognitive ability stood out in a study of Western diets and Alzheimer’s risk genes

A Western dietary pattern was associated with faster attention decline among older adults carrying the APOE ε4 allele, while no significant cognitive associations emerged for a Prudent dietary pattern. However, the Western diet association lost statistical significance after excluding participants with possible baseline cognitive impairment, making the finding exploratory.

Early-life stress rewires brain epigenetics to heighten sensitivity to future stress

11

Aug 2026

Early-life stress rewires brain epigenetics to heighten sensitivity to future stress

. Early-life stress increased SETD7 and H3K4me1 in the ventral tegmental area of mice, creating an epigenetically primed state that heightened later transcriptional, neuronal, and behavioral responses to stress. Reducing Setd7 during development lowered H3K4me1 and weakened these stress-sensitizing effects, identifying a mechanism that may help explain how early adversity leaves lasting biological effects.

What 38,000 trauma and incident records reveal about e-scooter safety

10

Aug 2026

What 38,000 trauma and incident records reveal about e-scooter safety

E-scooter riders admitted with moderate-to-severe trauma showed a distinct injury profile, with proportionally more traumatic brain, vascular, and internal organ injuries than motorcyclists and fewer fractures. Rental-scooter data also linked greater reported injury severity with younger age and female sex, while collision rates varied with area-level deprivation.

Broken String Biosciences launches BaseMap ABE to enable genome-wide off-target characterization in base editing therapeutic development

10

Aug 2026

Broken String Biosciences launches BaseMap ABE to enable genome-wide off-target characterization in base editing therapeutic development

Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, today announced the launch of BaseMap™ ABE. Built on the Company\'s INDUCE-seq® technology, BaseMap ABE extends the platform\'s capabilities to support adenine base editing (ABE) applications.

Semaglutide slows blood protein signature linked to future dementia risk

10

Aug 2026

Semaglutide slows blood protein signature linked to future dementia risk

A post hoc analysis of 2,970 older SELECT participants found that semaglutide slowed worsening of a 25-protein blood signature that predicts future dementia risk. Over 104 weeks, semaglutide produced larger effects on modeled 5-year than 20-year dementia risk, but whether these biomarker changes translate into less cognitive decline or dementia remains unknown.

Heavy rainfall and flooding raise infectious disease risks across Europe

10

Aug 2026

Heavy rainfall and flooding raise infectious disease risks across Europe

A rapid review of 14 studies found that heavy rainfall and flooding were associated with outbreaks and increased incidence of several infectious diseases across Europe, particularly campylobacteriosis and leptospirosis. The authors highlighted major evidence gaps and called for stronger One Health surveillance, public health communication, sanitation, and flood-response planning.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.